Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aldo-keto reductase family 1 member B10 (AKR1B10)
- Target
- AKR1B10
- Molecular classification
- Enzyme, Oxidoreductase, Aldo-keto reductase superfamily
01
Overview
Aldo-keto reductase family 1 member B10 (AKR1B10) is an NADPH-dependent enzyme of the aldo-keto reductase superfamily that catalyzes the reduction of carbonyl-containing compounds, especially aliphatic and aromatic aldehydes, protecting cells from oxidative stress and regulating lipid metabolism. It is highly expressed in the gastrointestinal tract and overexpressed in multiple cancers, where it has been associated with tumor progression, chemoresistance, and is under investigation as a prognostic biomarker
- Other names
- AKR1B10AKR1B11Aldose reductase-likeAldose reductase-related protein1.1.1.3001.1.1.54
02
Mechanism of action
Drugs inhibiting AKR1B10 act as enzyme inhibitors, reducing its activity in metabolic detoxification and possibly abrogating chemoresistance in certain cancers
03
Biological functions
Xenobiotic metabolismDetoxification of carbonyl compoundsReduction of aliphatic and aromatic aldehydesLipid metabolismProtection against oxidative stress
04
Disease associations
Cancer (including liver and digestive system cancers)CarcinogenesisChemoresistance
05
Safety considerations
Targeting AKR1B10 could affect detoxification and lipid metabolism, potentially leading to unintended metabolic disturbances or altered drug metabolism; impact on normal tissue expression remains a therapeutic challenge
06
Interacting drugs
No specific approved drugs directly targeting AKR1B10 were identified in the search results. However, AKR1B10 may influence drug resistance or metabolism of chemotherapeutic agents
07
Biomarkers
Overexpression in several cancers (e.g., hepatocellular carcinoma, colorectal cancer) is investigated as a biomarker for cancer prognosis and possibly treatment response
Beyond the preview
Go deeper on Aldo-keto reductase family 1 member B10 (AKR1B10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldo-keto reductase family 1 member B10 (AKR1B10).